Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
06/2010
06/02/2010CN101716148A Tirofiban hydrochloride freeze-dried powder injection preparation and preparation method thereof
06/02/2010CN101716147A Alprostadil liposome microsphere preparation
06/02/2010CN101716138A Injection containing tirofiban hydrochloride
06/02/2010CN101439178B Medicament containing Urapidil
06/02/2010CN101385718B Osmotic pump preparation composition for treating hyperlipemia
06/02/2010CN101322687B preparation of adenosine cyclophosphate oil emulsion for vein
06/02/2010CN101250288B Cyclovirobuxine D cyclodextrin or cyclodextrin derivative clathrate compound and preparation method thereof
06/02/2010CN101244057B 3-substituted oxygen group-3',4'-dimethoxy flavonoid compound with blood fat reducing function
06/02/2010CN101234106B Use of imidazolone compounds for treating cardiovascular and cerebrovascular diseases
06/02/2010CN101229354B Medicine for treating cerebral thrombosis and preparing method thereof
06/02/2010CN101229179B Use of oil orange phlorizin-B in preparing medicine
06/02/2010CN101204543B Medicament composition for varixoflowerlimb
06/02/2010CN101181434B Chinese medicine composition orally taken for curing hemorrhoid
06/02/2010CN101172111B Application of sterides in preparing medicament for treating cardiovascular and cerebrovascular diseases
06/02/2010CN101152171B Method of preparing mildronate injection
06/02/2010CN101129749B Compositions for treating functional ventricular premature beat and processes for producing the implant
06/02/2010CN101129437B Medicine for treating pile and method of preparing the same
06/02/2010CN101099836B Traditional Chinese medicine composition for treating ischemic apoplexy and preparation process thereof
06/02/2010CN101035761B 3,6-substituted 5-arylamino-1h-pyridine-2-one derivatives and related compounds as poly(ADP-ribose) polymerase(PARP) inhibitors in the treatment of tissue damage or diseage caused by necrosis or apopt
06/02/2010CN101028319B Chinese-medicine compound preparation against coronary heart disease and its production
06/01/2010US7729759 Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the BBB and cerebral blood flow
06/01/2010US7728133 Stable pharmaceutical compositions
06/01/2010US7728037 Alpha-ketoglutarates of active ingredients and compositions containing same
06/01/2010US7727999 substituted 1,3,8-triaza-spiro[4.5]decan-2-one compounds, used as selective serotonin receptor antagonists, used rfor the treatment of schizophrenia, psychosis, headaches, hypertension, thrombosis, vasospasm, depression, anxiety, sleep disorders and appetite disorders
06/01/2010US7727998 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
06/01/2010US7727965 C-glycosylisoflavones having alkylaminoalkoxyl substituent, preparation and use of the same
06/01/2010US7727275 Drug-delivery endovascular stent and method of forming the same
06/01/2010CA2553915C 3(2h)-pyridazinone compounds as vascular intimal hyperplasia inhibitor
06/01/2010CA2525867C Natural compounds and their derivatives for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications
06/01/2010CA2515841C Novel 2-pyridine carboxamide derivatives
06/01/2010CA2490120C Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
06/01/2010CA2457965C Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
06/01/2010CA2440680C Steroids as agonists for fxr
06/01/2010CA2426625C Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction
06/01/2010CA2420055C Fibrinogen-lowering agent
06/01/2010CA2409827C Arylmethylamine derivatives for use as tryptase inhibitors
06/01/2010CA2400626C Estrogen receptor modulators
06/01/2010CA2366750C (e)-styryl sulfone anticancer agents
05/2010
05/27/2010WO2010059967A2 Amide inhibitors of renin
05/27/2010WO2010059858A1 Manassantin compounds and methods of making and using same
05/27/2010WO2010059836A1 Substituted aza-bridged bicyclics for cardiovascular and cns disease
05/27/2010WO2010059627A1 Polar quinazolines as liver x receptors ( lxrs ) modulators
05/27/2010WO2010059610A1 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof
05/27/2010WO2010059602A2 Inhibitors of diacylglycerol acyltransferase
05/27/2010WO2010059372A2 Tryptase enzyme inhibiting aminopyridines
05/27/2010WO2010059245A2 Compositions and methods for treating or preventing radiation injury
05/27/2010WO2010059119A1 A combination of tert -butyl (2-{7- [2- (4-cyano-2- f luorophenoxy) ethyl] -9-oxa-3, 7-diazabicyclo [3.3.1] non-3- yl } ethyl) carbamate and certain antiarrhythmic benzofurans
05/27/2010WO2010058926A2 Pharmaceutical composition containing ginger extract or shogaol
05/27/2010WO2010058858A1 Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
05/27/2010WO2010058795A1 Antioxidant
05/27/2010WO2010058794A1 Antioxidant
05/27/2010WO2010058751A1 Pharmacologically acceptable salt of [1,3,4]oxadiazole compound or hydrate thereof
05/27/2010WO2010058517A1 NERVE CELL STIMULATOR COMPRISING IgG AND/OR Fc FRAGMENT OF IgG
05/27/2010WO2010058426A2 Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa
05/27/2010WO2010058318A1 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
05/27/2010WO2010057795A1 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
05/27/2010WO2010057418A1 A phenoxypyrimidine derivative, its preparation method and the use thereof
05/27/2010WO2010019914A3 Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
05/27/2010WO2010017055A3 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
05/27/2010WO2010013978A3 Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity
05/27/2010WO2010005480A9 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
05/27/2010WO2010003144A3 Hypotensive peptides from soy proteins and method of preparation
05/27/2010WO2009156462A3 Organic compounds
05/27/2010WO2009035927A8 Bis-cyclyl substituted ureas or amides as soluble epoxide hydrolase inhibitors
05/27/2010WO2008070780A9 Antagonist antibodies against ephb3
05/27/2010US20100130623 Production of stilbenes in plant hairy root cultures and other root cultures
05/27/2010US20100130621 Use of hydroxytyrosol as anti-aging agent
05/27/2010US20100130616 Salt of aliskiren with orotic acid
05/27/2010US20100130611 Omega 3 fatty acid formulations
05/27/2010US20100130577 Pyrazalone derivative formulations
05/27/2010US20100130563 Inhibitors of plasma kallikrein
05/27/2010US20100130555 Compositions and methods for treating or preventing hypoxic or ischemic injury
05/27/2010US20100130540 Azaquinolinone derivatives and uses thereof
05/27/2010US20100130517 New 4,8-diphenyl-polyazanaphthalene derivatives
05/27/2010US20100130516 Purinyl derivatives and their use as potassium channel modulators
05/27/2010US20100130504 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
05/27/2010US20100130501 Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivatives
05/27/2010US20100130500 Methods and compositions for the treatment of pulmonary hypertension of the newborn
05/27/2010US20100130496 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
05/27/2010US20100130493 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
05/27/2010US20100130487 Spiro-oxindole compounds and their uses as therapeutic agents
05/27/2010US20100130483 Novel diazabicyclic aryl derivatives
05/27/2010US20100130472 Bile acid recycling inhibitors for treatment of obesity and diabetes
05/27/2010US20100130471 Renin Inhibitors
05/27/2010US20100130467 Triazolotriazines as kinase inhibitors
05/27/2010US20100130453 Use of folates for the prevention and treatment of vascular diseases
05/27/2010US20100130436 Co-administration of ranolazine and cardiac glycosides
05/27/2010US20100130425 Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
05/27/2010US20100130424 Crhr2 peptide agonists and uses thereof
05/27/2010US20100130419 Artery- and Vein-Specific Proteins and Uses Therefor
05/27/2010US20100130414 Methods of Using E2F2 for the Treatment of Hypertension
05/27/2010US20100130410 Neural regeneration peptides and methods for their use
05/27/2010US20100129478 Plant Extracts and Methods and Uses Therefore
05/27/2010US20100129447 Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
05/27/2010US20100129417 Dihydroxybenzoate Polymers and Uses Thereof
05/27/2010US20100129365 Treatment of inflammation using bst2 inhibitor
05/27/2010US20100129356 Compositions and methods for modulating vascular development
05/27/2010CA2744388A1 Compositions and methods for treating or preventing radiation injury
05/27/2010CA2744343A1 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof
05/27/2010CA2743723A1 Inhibitors of diacylglycerol acyltransferase
1 ... 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 ... 1595